Masitinib in Oncology
Prostate cancer is one of the most common types of cancer in men. Masitinib is currently investigated in first-line metastatic castrate-resistant prostate cancer (mCRPC). This patient population consists of patients who have disease progression despite androgen depletion therapy (castration) treatment. There is still a need for more effective first-line treatment of mCRPC since recent therapies…